X4 Pharmaceuticals (XFOR)CFO sold ~$36K

~$36K

Approx. value · 8,543 sh @ $4.26

168K

Holds after · shares reported

Traded

Jun 30, 2026

Filed

Jul 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“At the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of shares available for issuance under the Plan by 1,500,000 shares.”
2. May 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“At the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of shares available for issuance under the Plan by 1,500,000 shares.”
3. May 12, 2026InsiderCFO sold ~$73K of XFOR shares in the open market
4. Jun 30, 2026 · this disclosureInsiderCFO sold ~$36K of XFOR shares in the open market

What came next

1. Jun 30, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026. In connection with Ms. Gold’s appointment, the size of the Company’s board of directors (the “Board”) was increased from five to six directors.”
2. Aug 12, 2026Insider · 2 peopleInsiders: 2 sales (~$320K)
3. Oct 1, 2026InsiderCFO sold ~$34K of XFOR shares in the open market
4. Oct 7, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 3 more items)
5. Oct 7, 20265% stakeFMR LLC reported a passive stake (13G) of 4.6%

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for X4 Pharmaceuticals

For X4 Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XFOR page.

Other recent filings by David Kirske, Chief Financial Officer

• SEC Form 4 at X4 Pharmaceuticals (XFOR)Oct 6, 2026
• SEC Form 4 at X4 Pharmaceuticals (XFOR)May 14, 2026

The full history of David Kirske, Chief Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at X4 Pharmaceuticals

• SEC Schedule 13GOct 7, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its XFOR page.